Fig. 3

Recombinant human IL-37 (rhIL-37) treatment in THP-1 macrophages and human synoviocytes. a–c Concentration of secreted IL-1β, IL-8, chemokine (C-C motif) ligand 2 (CCL2) and transforming growth factor β (TGF-β) in synoviocytes or THP-1 left untreated or treated with rhIL-37 for 3 h, and then incubation with monosodium urate (MSU), ATP or lipopolysaccharide (LPS) for a further 6 h or 18 h. Mean ± s.e.m. *P < 0.05 for rhIL-37 treatment compared to non-rh-IL-37 treatment